BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9574550)

  • 21. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
    Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
    Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
    J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma.
    Stahl S; Sacher T; Bechtold A; Protzer U; Ganss R; Hämmerling GJ; Arnold B; Garbi N
    Immunol Lett; 2009 Mar; 123(1):31-7. PubMed ID: 19428549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
    Zhang W; Yang H; Wang Z; Jim X
    Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
    Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
    Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
    J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.
    Toes RE; Offringa R; Blom RJ; Brandt RM; van der Eb AJ; Melief CJ; Kast WM
    J Immunol; 1995 Apr; 154(7):3396-405. PubMed ID: 7534797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
    Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional memory CD8+ T cells can be generated in vivo without evident T help.
    Andrews MR; Peters T; Khammanivong V; Leggatt GR; Frazer IH; Fernando GJ
    Vaccine; 2004 Dec; 23(6):739-42. PubMed ID: 15542197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
    Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system.
    Yamaoka A; Guan X; Takemoto S; Nishikawa M; Takakura Y
    J Control Release; 2010 Mar; 142(3):411-5. PubMed ID: 19913062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
    Hess PR; Boczkowski D; Nair SK; Snyder D; Gilboa E
    Cancer Immunol Immunother; 2006 Jun; 55(6):672-83. PubMed ID: 16133108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells.
    Ludewig B; Oehen S; Barchiesi F; Schwendener RA; Hengartner H; Zinkernagel RM
    J Immunol; 1999 Aug; 163(4):1839-44. PubMed ID: 10438917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.